Impact of Smoking Cessation Duration on Postoperative Complications in Lung Cancer Surgery
NCT ID: NCT06663020
Last Updated: 2025-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
248 participants
OBSERVATIONAL
2023-06-15
2025-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer
NCT05320458
Pulmonary and Extrapulmonary Impairments in Patients With Lung Cancer Awaiting Surgery
NCT04450719
Meaning of Recovery After Lung Cancer Surgery
NCT05453812
Postoperative Results of Surgical Treatment of Lung Cancer After 30 Days
NCT01413737
Investigation of the Effects of Tele-Yoga Training in Individuals With Lung Cancer Undergoing Lung Resection Surgery
NCT07001670
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study, patients will not be categorized based on smoking or cessation status alone but will be documented on a continuum by recording the exact number of days or weeks between their smoking cessation and their surgical procedure. The primary objective is to assess whether a specific duration of smoking cessation is associated with a reduced risk of postoperative complications, including both pulmonary and non-pulmonary complications. These complications are defined in two categories: respiratory (e.g., atelectasis, pneumonia, respiratory failure) and non-respiratory (e.g., atrial fibrillation, myocardial infarction, wound infection).
Patients with advanced chronic obstructive pulmonary disease (COPD), uncontrolled asthma, severe neuromuscular disease, advanced thoracic deformity, or severe cardiovascular disease will be excluded to minimize confounding variables. The study will also exclude patients with emergency surgeries, pregnant individuals, and those who have undergone prior thoracic surgeries.
The sample size calculation, performed using G\*Power software, determined a minimum of 248 participants would be needed to achieve a 95% confidence level and statistical power of 95%. Data analysis will include logistic regression to examine the relationship between smoking cessation duration and the occurrence of postoperative complications. Risk assessment tools, including the ARISCAT, Gupta Postoperative Pneumonia Risk, and Melbourne Group Scale, will be utilized to evaluate each patient's risk profile.
Data collection will focus on the following variables:
Patient demographics, comorbidities, neoadjuvant therapy, preoperative smoking history, lung function tests, operative and anesthesia times, intraoperative blood loss, pathological staging, and 30-day postoperative complications.
Quality assurance will involve source data verification from medical records to ensure accuracy, as well as routine data validation checks to maintain data consistency.
The statistical analysis will be guided by a comprehensive analysis plan, detailing the primary and secondary outcome evaluations. The findings aim to contribute to understanding the optimal smoking cessation timing to reduce surgical risks and enhance patient outcomes in lung cancer surgery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Smoking Cessation Duration
Participants are categorized based on their smoking status and the duration since they quit smoking prior to lung cancer surgery. This observational study focuses on evaluating the relationship between the duration of smoking cessation (measured in days or weeks) and the incidence of postoperative complications. Smoking cessation duration is recorded for each participant to determine its impact on surgical outcomes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients scheduled for elective surgery under general anesthesia due to NSCL.
* Patients classified as American Society of Anesthesiologists (ASA) I-III.
* Patients or their legally authorized representatives who have provided informed consent.
Exclusion Criteria
* Patients with severe and uncontrolled bronchial asthma.
* Patients with severe neuromuscular diseases or advanced thoracic deformity.
* Patients with severe heart disease classified as New York Heart Association (NYHA) Class III-IV.
* Patients with cognitive impairments.
* Patients undergoing emergency surgery.
* Pregnant patients.
* Patients with coagulopathy.
* Patients who have previously undergone video-assisted thoracoscopic surgery (VATS) and/or thoracotomy.
* Patients who died perioperatively.
* Patients or their legally authorized representatives who did not provide informed consent.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Caner İşevi, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Caner İşevi, MD
Thoracic Surgeon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ondokuz Mayis University Medical Faculty, Department of Thoracic Surgery
Samsun, Samsun, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B.30.2.ODM.0.20.08/19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.